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Abstract In order to evaluate the biological effects on some haemostasis factors of
antithrombotic-hemorheologicaltreatments on patients with vascular dementia, a
multicenter, randomized, double-blind,double-dummy,study comparing sulodexide
(Sdx, 50 mg bid orallyfor 6 months)and pentoxitjd]ine(Ptx, 400 mg tid orallyfor six
months) was carried out. Eighty-six patients, 46 in Sdx group, 40 in Ptx group,
fidfilling the NINDS-AIREN criteriafor probablevasculardementiawere evaluated.
Plasmafibrinogenlevelsshoweda significantreductionin both groups, in patientswith
highbasal levels(2350 mg/dl),the reductionbeingearlierin Sdx group (2nd month of
therapy)than in Ptx group (4th monthof therapy).In Sdx group a significantreduction
in factor VII-Ag (baseline102.8U/all;6th month 90.1 U/all)was also observed.Both
drugs induced a slight reduction in activated factor VII levels as well. A parallel
improvementof G.B.S. Rating Scale for dementiascores was observed in Sdx group.
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Vasculardementia(VaD) is a commoncause of dementiain the elderly,accountingfor at least
20Y0of all causes; its prevalenceincreasesnoticeablywith advancingage surpassingprevalence
rates of Alzheimer’sDisease in subjectsover 80 yearsof age (l). The conventionalvascularrisk
factors explainonly partiallythe causes of vasculardementia,a numberof differentmechanisms
beingpossiblyinvolved(2, 3).
On theorical ground there is a potential for the prevention and treatment of cerebrovascular
diseases(4); to this purpose drugs interferingwith hemostasiscould be of interest. Althoughthe
actualrole playedby thromboticdiseasein the developmentof VaD is stillnot completelyknown,
abnormallyelevated levelsof some coagulationparametershave recentlybeen described in this
pathologicalcondition(5). Specifically,high fibrinogenlevels (> 350 mg/dl) represent a major
vascularrisk factor for cardiovasculardiseases(6,7). No controlledtrials dealingwith treatment
of VaD by meansof drugsthat rdTecthemostasisare available.A pilot study (8) with aspirin(325
mg dailyfor 3 years) gave promisingresults.The xantinederivativepentoxifillinehas also been
successfullyused for treatmentof elderlypatientswith vasculardementia(9); in two other series
(10,11) this drug showed to be able to improve the haemorheologicalpattern (by decreasing
blood viscosity and improvingred blood cell deformability)parallel to a favorable trend of
psychobehavioralscoresin cognitivelyimpairedold subjects.The use of anticoagulanttherapy has
alsobeen proposed in senileand preseniledementia(12).
Sulodexideis a highlypurifiedpreparationcontaininga heparin fraction with a high afllnityfor
antithrombinIII (80°/0)and a dermatanfractionwith affinityfor heparincofactor II (20°/0)(13). In
vivo antiatheroscleroticeffects of sulodexide(14,15) may be related to a hypolipidemicactivity
linkedto lipoprotein-lipaserelease(16), confirmedby a reductionin plasmaand serumviscosity,
(17,18) a more rapid catabolism of cholesterol-richlipoproteinsby the liver (16) and an
antiproliferativeeffect on smooth musclecell types (14). Both in animalsand in human beings
sulodexideinhibitsactivatedfactor X withoutinfluencingthe activatedpartialthromboplastintime
and thrombintime (19-21). It also exerts a fibrinolyticactivity,expressedby tissue-plasminogen
activator inhibitor(t-PA) activationand plasminogenactivator inhibitor(PAI-1) inhibition(17,
21-23). Recently pharmacological evidence of antiaggregant activity has been described,
manifested as inhibitionof leukocyte pathway of platelet aggregation (24). Clinical trials in
peripheralobstructivearteriopathy(25,26) and preventionof myocardialreinfarction(27) have
providedevidenceof sulodexideeficacy in theseconditions.
With the primaryaim of evaluatingthe effect of antithrombotictherapies on some haemostatis
factor in VaD patients, we carried out a multicentredouble-blindstudy comparing sulodexide
with pentoxifjdline.
PATIENTSANDMETHODS
Ninety-threeelderlypatients(37 males, 56 females,mean age 75+5, range: 65-80 years) were
enrolledin the studyin four italiangeriatriccenters.Allof them !iMilledthe NINDS-AIREN (28)
diagnosticcriteria for probablevascular dementia;a Mini Mental State Examination(MMSE)
(29) score between 11 and 22 was used as inclusion criterion. They were not taking any
medication interferingwith platelet aggregation and/or coagulation;they did not suffer from
TIA/stroke episodes in the last three months.Patients were randomlyassigned to a six-month
treatment with sulodexide(Sdx; 50 mg bid orally) or pentoxifjdline(Ptx; 400 mg tid orally).
Accordingto high (> 350 mg/dl) or normal (<350 mg/dl) fibrinogenlevels at baseline,patients
were subdivided in two subgroups, expecting a reduction of at least 10% (or 40 mg/dl)
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of fibrinogenlevelsin patientswith highfibrinogen(primaryaim).
Clinicalparameters
Clinical efllcacy was assessed by means of Gottfries-Br&ne-Steen(GBS) Rating Scale for
Dementia(30). It is composedof three subscaleswhichgivecarefidinformationon motor (GBS-
m), intellectual(GBS-i)and emotional(GBS-e)disturbances;score for each subscalerangesfrom
O(no impairment)to 6 (maximumimpairment).The scale is widelyused in severalcountries;in
particularthe italianversionhas shown an excellentinter-raterreliability(31). Sincethe primary
aim of the study was to assess biologicaleffects rather than clinicalefficacyof Sulodexidein
vascular dementi~ we preferred to use this type of instrument - which gives substantial
informationon the general fictional state of the patient - rather than singlepsychometrictests
whichgive detailsof specificneuropsychologicalil.mctions.GBS was administeredat baseline,at
the 4thand 6* monthof therapy;at the end of treatment(t6)MMSE was also repeated.
Biolog”calparameters
Blood sampling:venous blood was obtainedbetween 8:00 and 10:00 am from the antecubital
veins by two syringe techniquesusing 19-gaugeneedles. All the coagulation and fibrinolysis
assays were carried out on blood collected in sodiumcitrate at a final concentrationof 3.8°A
(wt/vol).All plasmaspecimenswere centritiged at 4°C (except for activatedfactor VII, (FVIIa)
at room temperature) for 20 minutesat 2,000 g and stored at -80° C until assayed within 2-3
months. All assays were done in Milan, Italy. Coa Iation and fibrinolyticparameters were
Fevaluatedat baseline(to), after 2 (t2), 4 (t4) and 6 (t ) months.FVIIa was measured only in a
subsetof 20 patientsstudiedat one Centre(Perugia)at t“ and t6. Plasmafibrinogenwas measured
by a fibrinpolymerizationassay (BoehringerBiochemia).Factor VII antigen (FVII-Ag) plasma
levels were measured with an ELISA that is not tiected by FVII activation as previously
described (32). Plasminogenactivator inhibitortype 1 activity (PM-l) was measured by a
chromogenicmethod (Biopool, Ume&,Sweden). FVIIa was measured by a one-stage (33),
prothrombintime-basedassayusinga truncatedsolubleform of recombinanttissue factor (kindly
suppliedby Dr. Y. Nemerson,Mount SinaiHospitalMedicalSchool,New York, NY) that, upon
relipidation,reactswith factor VIIa but not with one-chainfactor VII.
RESULTS
A total numberof 93 patientswith probableVaD were randomized.Resultsrefers to 86 patients
(n. 46 in sulodexidegroup, n. 40 in pentoxyNlinegroup), tier seven patients dropped out (see
tolerability).In Table I detailsof the patientsstudiedare reported. As far as age, sex, education
and severityof cognitiveimpairmentwere concerned,no differenceswere detected between the
two groups. As regards to vascular profile of the patients, the two groups showed similar
distributionof major vascular risk factors, concomitantcardiovasculardiseases and CT scan
findings indicative of cerebrovascular disease. The majority of patients were afl’ectedby
subcorticalvasculardementiawith smalldeep infarctsand leukoencephalopathy.
Clinicalparameters
In Table II neuropsychologicalscores at differenttimes of the study are reported. GBS scores
showeda significantimprovementonly in the sulodexidegroup both at t4 and t6 (p<O.01vs to).
MMSE scores showed some positive but not relevant trend in both groups at the end of
treatment.
























































































Mean (+ SEM)NeuropsychologicalScoresObservedin VaD PatientsTreated with
SulodexideandPentoxifjdline
at Baseline(t”),at the Fourth (t4)and Sixth(t6)Month of Treatment
to ~4 t6
MMSE Sdx 17.6+ 0.4 --- 20+ 0.6
Ptx 18 + 0.4 .-. 20• 0.4
G.B.S. RatingScale
motor impairment Sdx 1.64+ 0.14 1.58*+ 0.14 1.54*+ (),16
Ptx 1.59l 0.13 1.53 * 0.14 1.46 + 0.17
intellectualimpairment Sdx 2.06 + 0.09 1.88** 0.09 1.79** 0.1
Ptx 1.98+ 0.08 1.95 * 0.1 1.87 + 0.12
emotionalimpairment Sdx 2.1 + 0.12 1.88* + 0.12 1.76*+ 0.12
Ptx 1.89+ 0.1 1.9 * 0.1 1.75 * 0.11
Patientsevaluated:46 Sdx,40 Ptx; * p<O.01M t“ (MannWhitney).
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Biolog”calparameters
In Table III fibrinogen,FVII-Ag, PAI-I and FVIIa levels are reported. As regards fibrinogen
levels,mean values did not differbetween the two groups. Dividingpatients in two subgroups
accordingto normal (<350 mg/dl) or high fibrinogenlevels (2350 mg/dl) (Fig. 1) a significant
reductionwas observedin patientswith higherlevels;the decreasewas earlier (t2) in Sdx group
comparedto Ptx group (t4).Both subgroupsmaintained these valuesuntil the end of treatments.
A significantreductionin factorVII-Ag levelswas observedat t6 as comparedto t“ (p<O.05)only
in sulodexidegroup.No significantvariationof PM-1 levelswere observedin any group. Finally,
FVIIa (evaluated in 10 patients treated with sulodexideand 10 with pentoxifilline)showed a
slighttrend toward a deerease in both groups. It shouldbe noted that baselinelevels of FVIIa
were remarkablyhigherthan referencevalues(3.1+1.1nghnl,p <0.001).
SAFETYAND TOLERABILITY
In sulodexidegroup 3 drop-outs due to melanoma,angina, heart failure were observed; two
episodesof mildgastralgia-not requiringdrug suspension-were also registered.In pentoxifjdline
group 3 drop-outsdue to gastralgia(2 pts.) and astheniawere obtained;one case of headacheand
3 cases of mild gastralgia did not require drug suspension. No abnormalities in routine
haematologicaland haematochemicalparameterswere observedin any subject.
DISCUSSION
In Table IV the main results obtained in this 6 month clinical-biologicaltrial carried out in
vasculardementiapatientstreated eitherwith sulodexideor pentoxifjdlineare summarized.
Both drugs are knownto have antithromboticand haemorheologicalproperties;in this studythey
have confirmedto be able to reduce high fibrinogenlevels,sulodexidedisclosingalso a positive
effect on some hemostasisparameters,namelyfactor VII-Ag, and on fictional parameters, as
documentedby GBS scores.
A slighttrend toward a decreaseof activatedfactor VII was observedin both treatmentgroups as
well, althoughthis tindingis relativeto a smallsubgroupof patients.
The existenceofa strong associationbetweenhighplasmafibrinogenlevelsand stroke (7,34), as
well as the role of factor VII coagulantactivityas major risk factor for cardiovascularevents
(35,36), is now welldocumented.Nevertheless,scantyis the knowledgeof the actual relevanceof
alteredhemostasisfactorson pathophysiologyof vasculardementia,as well as the impactof anti-
thromboticdrugson this condition.
In a recent investigation,hemostasis abnormalitiessimilar to those found in patients with
atherothromboticdiseaseswere observedin patientswith vasculardementia(37), suggestingthat
these alterations can havea role in the pathogenesisof the disorder. In particular,highlevelsof
activated Factor VII could be explainedif we assumethat vascular injury induces exposure of
tissue factor thus acceleratingformationof activatedFactor VII/tissue factor pathway inhibitor
(TFPI) complex.TFPI, a major inhibitorof activatedFactor VII, is releasedin plasmaby heparin
and glycosaminoglycans(38), therefore, we might speculate that Sdx, a highly purified
glicosaminoglycanpreparation,by inducinga release of TFPI, influencesFactor VII zymogen
levels.
Few years ago vasculardementiahas been definedas a form of preventablesenility,being the last
clinicalstep after the brain-at-riskstage and the pre-dementiastage (4). In this perspectiveaimed
at preventingvasculardementia,one shouldconsiderto treat also patientswho are in the stages
precedingvasculardementia.Due to the potential clinical relevanceofa successfldltreatmentof
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TABLEIII
HaemostasisParametersMeasuredat DifferentTimesof the Study
pts n“ to t2 ~4 t6
“l?ibrinogen Sdx 49 346 + 10 327 + 10 320 + 12 332 + 14
(mg/dl)_ Ptx 44 343 + 12 345 + 12 312 + 10 322 + 11
<350 mg/dl S& 22 288 7 301 4 9 289 =+=7 301 +13
Ptx 21 291 =E11 302 * 13 291 &10 303 h 17
~ 350 mg/dl Sdx 27 408 * 9 355*+ 17 358* =E21 367* =+=23
Ptx 23 394 *13 394 k 13 340* %17 344* k 13
~actor VII-Ag Sdx 49 102.8&4.3 99.1*+ 5.3 100.7+ 4.8 90.1*+ 4.7
(U/all) Ptx 44 101.0+ 4.7 104.0 + 5.1 97.6 + 4.7 89.6 + 5.8
Plasminogenactivator Sdx 49 12.1(10-17) 12.5(9-18) 12.1(11-16) 11.0(8-15)
inhibitortype 1 (IU/ml) Ptx 44 11.8(9-16) 11.4(10-15) 12.4(10-18) 11.9(10-14)
~ctived factor VII Sdx 10 4.4 * 0.7 --- --- 3.3 + 0.7
@g/ml) Ptx 10 4.3 + 0.7 --- .. . 3.1 + 0.4
Fibrinogen,FVII antigenandFVIIa: means+ SEM
PM-1: geometricmeans(95% confidenceintervals)
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FIG. 1
TimeCourseof MeanFibrinogenLevels
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TABLEIV - Summaryof ResultsObtained
231
Sulodexide Pentoxifj41ine
Biological highfibrinogen(> 350 mg/dl) u u* u U**
parameters Factor VII-Ag. Uu =
activatedFactor VII “u =U
PM-I — .
Clinical GBS motor impairment Uu =
parameters intellectualimpairment Uu =
emotionalimpairment Uu =
UU statisticallysignificantreduction
* obtainedat the 2nd monthof treatment
** obtainedat the 4th monthOftreatment
cerebrovasculardiseases, the positive results obtained in this study are worth of note. Large
prospectiveclinicaltrials based on these phathophysiologicalconsiderationsare therefore highly
recommended.
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